vs
BADGER METER INC（BMI）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
BADGER METER INC的季度营收约是Ultragenyx Pharmaceutical Inc.的1.1倍（$234.1M vs $207.3M），BADGER METER INC净利率更高（14.3% vs -62.0%，领先76.4%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 14.1%），BADGER METER INC自由现金流更多（$50.8M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 9.2%）
Badger Meter Inc是全球领先的流量测量与控制解决方案供应商，主要服务水务企业、工业、商业及住宅客户群体，核心产品包括智能水表、物联网使用监测系统及配套软件，可帮助客户追踪资源消耗、减少浪费、提升运营效率，核心市场覆盖北美、欧洲及亚太地区。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
BMI vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $234.1M | $207.3M |
| 净利润 | $33.6M | $-128.6M |
| 毛利率 | 39.7% | — |
| 营业利润率 | 18.4% | -54.7% |
| 净利率 | 14.3% | -62.0% |
| 营收同比 | 14.1% | 25.9% |
| 净利润同比 | 9.3% | 3.5% |
| 每股收益（稀释后） | $1.13 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $234.1M | $207.3M | ||
| Q3 25 | $222.2M | $159.9M | ||
| Q2 25 | $238.1M | $166.5M | ||
| Q1 25 | $222.2M | $139.3M | ||
| Q4 24 | $205.2M | $164.6M | ||
| Q3 24 | $208.4M | $139.5M | ||
| Q2 24 | $216.7M | $147.0M | ||
| Q1 24 | $196.3M | $108.8M |
| Q4 25 | $33.6M | $-128.6M | ||
| Q3 25 | $35.1M | $-180.4M | ||
| Q2 25 | $34.6M | $-115.0M | ||
| Q1 25 | $38.4M | $-151.1M | ||
| Q4 24 | $30.7M | $-133.2M | ||
| Q3 24 | $32.0M | $-133.5M | ||
| Q2 24 | $33.1M | $-131.6M | ||
| Q1 24 | $29.1M | $-170.7M |
| Q4 25 | 39.7% | — | ||
| Q3 25 | 43.1% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 42.9% | — | ||
| Q4 24 | 40.3% | — | ||
| Q3 24 | 40.2% | — | ||
| Q2 24 | 39.4% | — | ||
| Q1 24 | 39.3% | — |
| Q4 25 | 18.4% | -54.7% | ||
| Q3 25 | 20.7% | -106.9% | ||
| Q2 25 | 18.8% | -64.8% | ||
| Q1 25 | 22.2% | -102.6% | ||
| Q4 24 | 19.1% | -74.3% | ||
| Q3 24 | 19.5% | -94.6% | ||
| Q2 24 | 19.2% | -79.1% | ||
| Q1 24 | 18.6% | -151.9% |
| Q4 25 | 14.3% | -62.0% | ||
| Q3 25 | 15.8% | -112.8% | ||
| Q2 25 | 14.5% | -69.0% | ||
| Q1 25 | 17.3% | -108.5% | ||
| Q4 24 | 15.0% | -80.9% | ||
| Q3 24 | 15.4% | -95.7% | ||
| Q2 24 | 15.3% | -89.5% | ||
| Q1 24 | 14.8% | -156.8% |
| Q4 25 | $1.13 | $-1.28 | ||
| Q3 25 | $1.19 | $-1.81 | ||
| Q2 25 | $1.17 | $-1.17 | ||
| Q1 25 | $1.30 | $-1.57 | ||
| Q4 24 | $1.04 | $-1.34 | ||
| Q3 24 | $1.08 | $-1.40 | ||
| Q2 24 | $1.12 | $-1.52 | ||
| Q1 24 | $0.99 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $713.3M | $-80.0M |
| 总资产 | $973.6M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
| Q4 25 | $713.3M | $-80.0M | ||
| Q3 25 | $702.5M | $9.2M | ||
| Q2 25 | $677.6M | $151.3M | ||
| Q1 25 | $641.7M | $144.2M | ||
| Q4 24 | $606.2M | $255.0M | ||
| Q3 24 | $591.2M | $346.8M | ||
| Q2 24 | $563.1M | $432.4M | ||
| Q1 24 | $535.6M | $140.3M |
| Q4 25 | $973.6M | $1.5B | ||
| Q3 25 | $978.3M | $1.2B | ||
| Q2 25 | $936.4M | $1.3B | ||
| Q1 25 | $899.6M | $1.3B | ||
| Q4 24 | $816.4M | $1.5B | ||
| Q3 24 | $802.9M | $1.5B | ||
| Q2 24 | $781.3M | $1.6B | ||
| Q1 24 | $743.5M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $54.8M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $50.8M | $-100.8M |
| 自由现金流率自由现金流/营收 | 21.7% | -48.6% |
| 资本支出强度资本支出/营收 | 1.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.63× | — |
| 过去12个月自由现金流最近4个季度 | $169.7M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $54.8M | $-99.8M | ||
| Q3 25 | $51.3M | $-91.4M | ||
| Q2 25 | $44.6M | $-108.3M | ||
| Q1 25 | $33.0M | $-166.5M | ||
| Q4 24 | $52.1M | $-79.3M | ||
| Q3 24 | $45.1M | $-67.0M | ||
| Q2 24 | $36.4M | $-77.0M | ||
| Q1 24 | $21.5M | $-190.7M |
| Q4 25 | $50.8M | $-100.8M | ||
| Q3 25 | $48.2M | $-92.7M | ||
| Q2 25 | $40.6M | $-110.7M | ||
| Q1 25 | $30.1M | $-167.8M | ||
| Q4 24 | $47.4M | $-79.5M | ||
| Q3 24 | $42.0M | $-68.6M | ||
| Q2 24 | $34.1M | $-79.0M | ||
| Q1 24 | $18.8M | $-193.9M |
| Q4 25 | 21.7% | -48.6% | ||
| Q3 25 | 21.7% | -58.0% | ||
| Q2 25 | 17.1% | -66.5% | ||
| Q1 25 | 13.5% | -120.5% | ||
| Q4 24 | 23.1% | -48.3% | ||
| Q3 24 | 20.1% | -49.2% | ||
| Q2 24 | 15.7% | -53.7% | ||
| Q1 24 | 9.6% | -178.2% |
| Q4 25 | 1.7% | 0.5% | ||
| Q3 25 | 1.4% | 0.8% | ||
| Q2 25 | 1.7% | 1.5% | ||
| Q1 25 | 1.3% | 1.0% | ||
| Q4 24 | 2.3% | 0.1% | ||
| Q3 24 | 1.5% | 1.2% | ||
| Q2 24 | 1.1% | 1.4% | ||
| Q1 24 | 1.4% | 3.0% |
| Q4 25 | 1.63× | — | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.29× | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | 1.70× | — | ||
| Q3 24 | 1.41× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | 0.74× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMI
| Transferred At Point In Time | $198.6M | 85% |
| Transferred Over Time | $22.1M | 9% |
| Other | $13.4M | 6% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
